Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 28, 2012; 18(36): 5058-5064
Published online Sep 28, 2012. doi: 10.3748/wjg.v18.i36.5058
Table 1 Polymerase chain reaction primers used for genotyping
Genetic variantSense primersAntisense primers
Arg702Trp5’-CAT CTG AGA AGG CCC TGC TC(C/T)-3’5’-CAG ACA CCA GCG GGC ACA-3’
Gly908Arg5’-TTG GCC TTT TCA GAT TCT GG(G/C)-3’5’-CCC CTC GTC ACC CAC TCT G-3’
Leu1007fs insCNot availableNot available
IGR2060a15’-CTC ATT ACA TCC TTG CAA CCC T(G/C)-3’5’-GAC ACA TGG TGT GAG CTC AGT CA-3’
IGR3081a15’-TCG CGT GAG TCC TAT TCT TTC T(T/G)-3’5’-TTC ATA CTT CCA GCA GCG GG-3’
Table 2 Characteristics for Crohn’s disease patients still in remission and those who lost remission after discontinuing infliximab
CharacteristicRemaining in remission following discontinuing infliximab (n = 6)Lost remission following discontinuing infliximab (n = 8)
Male:female (n)4:24:4
Age of Crohn’s disease onset (yr), mean (range)30 (14-47)26 (15-38)
Current age (yr), mean (range)53 (41-60)41 (25-57)
Duration of disease prior to first infliximab infusion (yr), mean ± SD15 ± 8.010.1 ± 11.3
Age at first infliximab infusion (yr), mean ± SD45 ± 7.636 ± 11.1
Number of infusions, mean ± SD5.7 ± 3.54.7 ± 1.7
Duration of infliximab treatment (mo), mean (range)12 (3.6-36.2)7.2 (1.5-15)
Duration of remission after infliximab stopped (yr), mean ± SD8.1 ± 2.611.0 ± 0.62
Disease distribution, n (%)
Ileum2 (33)2 (25)
Ileo-colonic3 (50)4 (50)
Colon1 (17)2 (25)
Current medications in patients who lost remission, n
Adalimumab4
Infliximab2
Azathioprine alone1
No Biological or immunosuppressive therapy31
Table 3 5q31 and nucleotide-binding oligomerization domain 2/caspase activation recruitment domain 15 variants in crohn’s disease patients still in remission and those who lost remission after discontinuing infliximab
VariantRemaining in remission following discontinuing infliximab (n = 6)Lost remission following discontinuing infliximab (n = 8)Odds ratioP value
Arg702Trp1.501.00
Homozygous wild type, CC (%)4 (67)6 (75)
Heterozygous, CT (%)2 (33)2 (25)
Homozygous mutant, TT (%)00
Gly908Arg--
Homozygous wild type, GG (%)6 (100)8 (100)
Leu1007fs insC2 (33)2 (25)1.501.00
IGR2060a11.671.00
Homozygous wild type, GG (%)1 (17)2 (25)
Heterozygous, GC (%)3 (50)2 (25)
Homozygous mutant, CC (%)2 (33)4 (50)
IGR3081a1-0.47
Homozygous wild type, TT (%)02 (25)
Heterozygous, GT (%)4 (66)2 (25)
Homozygous mutant, GG (%)2 (33)4 (50)